Our Sponsors:

Read more »

Trending Stories

Our Members

Many thanks to Susan McBain and Peter Dunphy some of our many supporters.


Most Commented


    Can Washington get its life sciences groove back?

    Both candidates for governor say they will help biotech and biomedical research in Washington state. But formerly robust state investments have dwindled as leaders divert tobacco-settlement money.
    The state's Life Sciences Discovery Fund has supported research on cancer and other health issues at the Fred Hutchinson Cancer Research Center, the University of Washington, and a host of other organizations around the state.

    The state's Life Sciences Discovery Fund has supported research on cancer and other health issues at the Fred Hutchinson Cancer Research Center, the University of Washington, and a host of other organizations around the state. Sea turtle/Flickr

    The map shows locations where Life Sciences Discovery Fund has made investments.

    The map shows locations where Life Sciences Discovery Fund has made investments. Life Sciences Discovery Fund

    Jay Inslee's plans to help biotech in Washington are a bit more ambitious than Rob McKenna's proposals. But the state government's budget woes — especially in education — means that the Legislature likely won't allocate much money to biotech in the upcoming session.

    McKenna and Inslee outlined their biotech plans Friday to the Washington Biotechnology and Biomedical Association annual governor's summit in Bellevue. Both candidates want to keep research and development tax credits intact. Both said the state's education system needs improvement to send more students into biotechnology. Both said Washington's universities need more money to accept and teach biotech students. Both said the economy needs to improve to increase that flow of science students  —  citing their broad economic development measures as ways to do so.

    "I believe this industry is a wellspring of economic potential," Inslee said.

    McKenna pointed to the state's fees and taxes as a drag on biotech. "This is one of the most expensive states in which to do business. ... I don't think we need to be one of the cheapest states. But we don't need to be one of the most expensive," McKenna said. 

    Inslee said he would create a designated office to provide state help in finding private capital and networking opportunities for biotech bsuinesses. He also proposed allowing fledgling biotech businesses to sell their research and development tax credits to established tech firms  —  essentially old firms providing money to young firms that have no revenue,  while getting their tax credits in return. Inslee also is looking into removing legal restrictions that hamper universities from licensing their research for private biotech ventures. "We have artificial restrictions on this great research,"Inslee said.

    McKenna criticized Inslee's biotech office proposal. "I'm leery of the approach he's taking of picking winners and losers. ... I'm afraid it'll result in the cronyism that we see in Washington, D.C.," he said.

    Life sciences make up Washington's fifth largest business sector, according to the Washington Biotechnology and Biomedical Association (WBBA).

    WBBA figures show about 34,000 direct biotech jobs in the state, a number that grows to roughly 92,000 jobs when the ripple effects and support jobs are added. The biotech industry contributes roughly $11 billion to Washington's economy with more than 400 drug research and medical technology firms across the state.

    Biotech is one of Washington's strongest industrial sectors job-wise. The state's workforce dipped 2 percent from January 2007 to January 2012. Meanwhile, life science jobs grew 12 percent in the same period, according to Washington Research Council figures.

    Even though this sector is growing, it won't be able to count on much financial help from the state. That's because the source of state's biotech aid is already being tapped into for other Washington government  expenses. Washington's Legislature will face $2 billion to $6 billion in revenue shortfalls when it tackles the state's 2013-2015 budget early next year. The bulk of that shortfall will be due to last January's Washington Supreme Court ruling that says the state is not meeting its constitutional duties to fund basic education. As a result, the Legislature will have to find billions of dollars in worth of new revenue and budget cuts in the upcoming session.

    Inslee and McKenna have both ruled out calling for new taxes, claiming the needed extra revenue can be raised by an improved economy. Outgoing Gov.Chris Gregoire contends that claim is unrealistic.

    The state has a Life Sciences Discovery Fund set up to help biotech research. In 2005, Gregoire and the Legislature established a program to spend $350 million — supposedly $35 million a year from 2008 though 2017 — to bolster life sciences research and turn that research into jobs. The money comes from part of an annual lawsuit settlement payment from tobacco companies to numerous states, including Washington.

    The fund finances projects that cover a broad spectrum of health-related undertakings: brain, breast cancer, and blood and diabetes research; developing technologies for human cell therapies; creating gluten-free wheat; improving surgery safety in at least three-quarters of the state's hospitals; helping rural communities deal with mental health and substance abuse issues; developing "smart home" technology for the elderly; and providing gene sequencing equipment for researchers. Other research addresses early detection of tooth decay and systemic shock as well as help in diagnosing back pain. One effort has been to teach better CPR techniques to first responders.

    Like what you just read? Support high quality local journalism. Become a member of Crosscut today!


    Posted Tue, Oct 30, 8:30 a.m. Inappropriate

    Seems to me that the biotech industry, which we've been pumping for more than 2 decades now, has really not delivered on its promise. There were a few favorite son startups that became midsized and then just didn't make the products they intended and got gobbled up for a song.

    The industry that is growing right now and which Washington has totally missed out on is hydrogen and fuel cells...which are rapidly moving towards commercialization and production in the auto and stationary power sectors. I myself tried to spur interest with a well known venture firm back in 2006 but was stonewalled.

    The other area that Washington lags in is social media...there's a Facebook satellite office, and maybe we can build on that, but not much else.


    Posted Tue, Oct 30, 11:48 a.m. Inappropriate

    The tobacco settlement and creation of state slush funds is one of the largest abuses of the American legal and justice system ever...hopefully it all ends in a few years. And the billions of shortfall just to fund 'basic education' is more political posturing than legal truth. And biotech is far less productive than sheer high tech Google and Apple leaps and bounds. Beware false promises, false hopes, and false premises.


    Login or register to add your voice to the conversation.

    Join Crosscut now!
    Subscribe to our Newsletter

    Follow Us »